Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.

Trial Details

NCT ID
NCT03942653
Phase
PHASE2
Sponsor
Manish Patel
Status
RECRUITING
Cancer Type
Salivary Gland Head and Neck Cancer
Interventions
  • Goserelin Acetate
  • Pembrolizumab
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Ann Arbor, Michigan, United States|42.27756,-83.74088

Key Eligibility Criteria

  • Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the infor…
  • Age ≥ 18 years at the time of consent.
  • Locally advanced, recurrent, or metastatic salivary gland carcinoma that is not amenable to curative surgery or radiation
  • ECOG Performance Status of 0 or 1 within 28 days prior to registration.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Salivary Gland Head and Neck Cancer Trials on Trialify →